Chad vs Türkiye: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Chad
2.2%
in 2024
Türkiye
0.0%
in 2024
Chad rank
11th
Türkiye rank
13th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Chad
- Türkiye
How they compare
Chad currently reports 2.2% against 0.0% in Türkiye, a difference of 2.2%.
Across all 10 years both countries report, Chad has been ahead every year.
Chad ranks 11th and Türkiye ranks 13th of 215 countries.
Chad has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Chad | Türkiye | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4.1% | 0.1% | 4.0% | Chad |
| 2020s | 3.0% | 0.1% | 2.9% | Chad |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Chad or Türkiye?
- Chad, at 2.2% against 0.0% in Türkiye as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Chad and Türkiye?
- 2.2%, with Chad ahead.
- How many years of comparable data are there for Chad and Türkiye?
- 10 years are reported by both, from 2015 to 2024.
- How do Chad and Türkiye rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Chad ranks 11th and Türkiye ranks 13th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.